Select Page

KISQALI® (ribociclib) tablets, for oral use. Initial U.S. Approval: 2017

KISQALI® (ribociclib) tablets, for oral use. Initial U.S. Approval: 2017

ENHERTU is a prescription medicine. ENHERTU is used to treat of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

INDICATIONS AND USAGE
KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
DOSAGE FORMS & STRENGTHS
Tablets: 200 mg
Manufactured By: Novartis Pharmaceuticals Corporation
Prescribing Information URL: Click Here

Procedure to buy ONTRUZANT (trastuzumab-dttb) for injection?
To buy ONTRUZANT (trastuzumab-dttb) for injection, patients can simply fill the order form or can send mail at info@bioniquehealthcare.com. or can also send Whatsapp message at +91 96677 50889. You will get reply within few hours with pricing and procedure details. Note:- the order will be confirmed only after the receipt of valid prescription of doctor.

Category:

Trastuzumab-dttb was first approved as a 150 mg single-dose vial by the FDA in January 2019 across all eligible indications, mainly adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.

Trastuzumab-dttb is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative breast cancer, including: As a part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel. With docetaxel and carboplatin. As a single agent following multi-modality anthracycline-based therapy.

In addition, trastuzumab-dttb is indicated in combination with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer and as a single agent for the treatment of HER2-overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease.

Documentation

  1. Doctor’s Prescription – We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.
  2. Patient’s Medical history – We would require all test reports and medical reports of the patient for last 3 months.
  3. Patient’s Identity card – We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

For Overseas Patient

Can I get anti-cancer medicines even if I am not based in India?

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. The Bionique Healthcare can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find the best price of –

KISQALI® (ribociclib) tablets in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
KISQALI® (ribociclib) tablets in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
KISQALI® (ribociclib) tablets in North America – Mexico.
KISQALI® (ribociclib) tablets in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
KISQALI® (ribociclib) tablets in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
KISQALI® (ribociclib) tablets in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
KISQALI® (ribociclib) tablets in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
KISQALI® (ribociclib) tablets in Australia and New Zealand.

For Indian Patient

Ani-Cancer KISQALI® (ribociclib) tablets are prescription drug. 

We facilitate by-

  • Helping in documentation to import the medicine for personal use.
  • Finding Genuine and reliable source in USA, Europe and Japan.
  • Ensuring 100% transparency.

KISQALI® (ribociclib) tablets can be shipped to Ahmedabad, Bangalore, Chennai, Cochin, Hyderabad, Delhi, Haryana, Jaipur, Jammu and Kashmir, Himachal Pradesh, Kolkata, Lucknow, Mumbai, Pune, Punjab and other cities in India. Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. 

Reviews

There are no reviews yet.

Be the first to review “KISQALI® (ribociclib) tablets, for oral use. Initial U.S. Approval: 2017”

Your email address will not be published. Required fields are marked *

Anti-Cancer Medicine Supplier.

Bionique Healthcare is a consulting pharmaceutical company which assist Patients in accessing medicines in India. Bionique Healthcare facilitates such access only against valid prescriptions in conformity with all local laws and regulations.

Patients/ Clinicians / Researchers can contact Bionique at +91 9667750889 or write to at – info@bioniquehealthcare.com.

Product Disclaimer

Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturer or licensee. 

Bionique Healthcare does not lay any claim on them.